Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18922570 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
Condition: Colorectal Adenoma
Interventions: Drug: MK0966; Rofecoxib / Duration of Treatment: 156 weeks;   Drug: Placebo/ Duration of Treatment: 156 weeks

Indicates status has not been verified in more than two years